{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:57:35Z","timestamp":1779217055081,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005721","name":"Universit\u00e4t Bielefeld","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcemia (FHH) are key differential diagnoses in parathyroid hormone (PTH)-mediated hypercalcemia. While PHPT often arises from single-gland parathyroid adenomas, CaSR mutations are typically associated with FHH. However, the coexistence of CaSR mutations and PHPT represents an unusual presentation, and the variability in their clinical impact remains underexplored. This report highlights two distinct cases of heterozygous CaSR mutations, including a novel mutation, shedding light on their potential roles in disease pathogenesis and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>The first case involves a 54-year-old Caucasian female with a heterozygous Ala986Ser CaSR mutation, PHPT due to a parathyroid adenoma, and autoimmune Graves\u2019 disease. She presented with recurrent sicca syndrome, fatigue, hypercalcemia, elevated PTH, and hypercalciuria. Post-parathyroidectomy, persistent hypercalcemia and abnormal laboratory findings, alongside TRAK and TG antibodies, suggested a multifactorial pathogenesis. Imaging showed patchy hypoechoic thyroid parenchyma and recurrent adenoma. DXA revealed mild osteopenia, while calcimimetic therapy with cinacalcet was initiated but subsequently discontinued due to gastrointestinal intolerance. This unusual overlap of autoimmune and genetic factors emphasizes the complexity of managing PHPT with coexisting CaSR mutations.<\/jats:p>\n                    <jats:p>The second case describes a 52-year-old Caucasian male with a heterozygous Glu1011Gln CaSR mutation. He presented with severe hypercalcemia, elevated PTH, nausea, and diffuse musculoskeletal pain. Imaging revealed no adenomas, but sonography later identified a hypoechoic lesion with central vascularization, suggestive of a potential adenoma. Initial symptomatic improvement occurred despite persistently elevated biochemical markers; however, clinical worsening with recurrent abdominal symptoms and progressive bone mineral density loss was observed during follow-up. This case highlights a possible association between CaSR variants and sporadic adenomas, underscoring diagnostic complexity rather than direct causality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These cases highlight the complex clinical presentations in patients carrying CaSR variants and autoimmune components, suggesting a broader spectrum of clinical phenotypes and pathogenesis than previously understood. The findings emphasize the importance of genetic analysis in atypical cases and underscore the need for further research into the role of CaSR mutations in PHPT, which may inform future diagnostic and therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-06062-3","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T05:21:47Z","timestamp":1777094507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Divergent clinical presentations and management of calcium-sensing receptor (CaSR) mutations: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Stylianos","family":"Kopanos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Feldkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"6062_CR1","doi-asserted-by":"crossref","unstructured":"Blau JE, Simonds WF. Familial Hyperparathyroidism. Front Endocrinol. 2021;12.","DOI":"10.3389\/fendo.2021.623667"},{"key":"6062_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ando.2022.05.003","volume":"83","author":"S Lemoine","year":"2022","unstructured":"Lemoine S, Figueres L, Bacchetta J, Frey S, Dubourg L. Calcium homeostasis and hyperparathyroidism: nephrologic and endocrinologic points of view. Ann Endocrinol. 2022;83:237\u201343.","journal-title":"Ann Endocrinol"},{"key":"6062_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s42000-023-00508-9","volume":"23","author":"KA English","year":"2024","unstructured":"English KA, Lines KE, Thakker RV. Genetics of hereditary forms of primary hyperparathyroidism. Hormones. 2024;23:3.","journal-title":"Hormones"},{"key":"6062_CR4","doi-asserted-by":"crossref","unstructured":"H\u00f6ppner J, Sinningen K, Raimann A, Obermayer-Pietsch B, Grasemann C. Disorders of the calcium sensing signaling pathway: from familial hypocalciuric hypercalcemia (FHH) to life threatening conditions in infancy. J Clin Med. 2022;11.","DOI":"10.3390\/jcm11092595"},{"key":"6062_CR5","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1210\/me.2012-1232","volume":"26","author":"MP Grant","year":"2012","unstructured":"Grant MP, Stepanchick A, Breitwieser GE. Calcium signaling regulates trafficking of Familial Hypocalciuric Hypercalcemia (FHH) mutants of the calcium sensing receptor. Mol Endocrinol. 2012;26:2081\u201391.","journal-title":"Mol Endocrinol"},{"key":"6062_CR6","doi-asserted-by":"crossref","unstructured":"Sumida A, Iizuka K, Kato T, Liu Y, Kubota S, Kubota-Okamoto S, et al. A case of familial hypocalciuric hypercalcemia type 1 due to CASR p.Pro55Leu mutation. BMC Endocr Disord. 2022;22.","DOI":"10.1186\/s12902-022-01077-5"},{"key":"6062_CR7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12020-017-1241-5","volume":"55","author":"A Szalat","year":"2017","unstructured":"Szalat A, Shpitzen S, Tsur A, Koren IZ, Shilo S, Tripto-Shkolnik L, et al. Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected Familial Hypocalciuric Hypercalcemia. Endocrine. 2017;55:741\u20137.","journal-title":"Endocrine"},{"key":"6062_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00198-019-05170-9","volume":"31","author":"A Mahajan","year":"2020","unstructured":"Mahajan A, Buse J, Kline G. Parathyroid hormone-dependent Familial Hypercalcemia with low measured PTH levels and a presumptive novel pathogenic mutation in CaSR. Osteoporos Int. 2020;31:203\u20137.","journal-title":"Osteoporos Int"},{"key":"6062_CR9","doi-asserted-by":"crossref","unstructured":"Wu Y, Zhang C, Huang X, Cao L, Liu S, Zhong P. Autosomal dominant hypocalcemia with a novel CASR mutation: a case study and literature review. J Int Med Res. 2022;50.","DOI":"10.1177\/03000605221110489"},{"key":"6062_CR10","unstructured":"Zanchelli F, Giudicissi A, Neri L, Sgarlato V, Bruno PF, Ruggeri M, et al. [Familial hypocalciuric hypercalcemia type 1 likely secondary to a new inactivating mutation of CASR]. G Ital Nefrol Organo Uff Della Soc Ital Nefrol. 2024;41 :40\u20134."},{"key":"6062_CR11","doi-asserted-by":"crossref","unstructured":"Conigrave AD. The calcium-sensing receptor and the parathyroid: past, present, future. Front Physiol. 2016;7.","DOI":"10.3389\/fphys.2016.00563"},{"key":"6062_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/MNH.0000000000000998","volume":"33","author":"H Dimke","year":"2024","unstructured":"Dimke H. New insights into renal calcium-sensing receptor activation. Curr Opin Nephrol Hypertens. 2024;33:433\u201340.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"6062_CR13","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JME-19-0104","volume":"63","author":"CM Gorvin","year":"2019","unstructured":"Gorvin CM, Gorvin CM. Molecular and clinical insights from studies of calcium-sensing receptor mutations. J Mol Endocrinol. 2019;63:R1-16.","journal-title":"J Mol Endocrinol"},{"key":"6062_CR14","unstructured":"Kayed HAA, Islam SU, Akanmode OJ, Ezike LA, Mirza L. Novel mutation in the calcium-sensing receptor gene associated with familial hypocalciuric hypercalcemia. Cureus. 2024;16."},{"key":"6062_CR15","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2017-01606","volume":"102","author":"SJ Marx","year":"2017","unstructured":"Marx SJ. Calcimimetic use in familial hypocalciuric hypercalcemia\u2014a perspective in endocrinology. J Clin Endocrinol Metab. 2017;102:3933\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"6062_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41574-018-0115-0","volume":"15","author":"FM Hannan","year":"2018","unstructured":"Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol. 2018;15:33\u201351.","journal-title":"Nat Rev Endocrinol"},{"key":"6062_CR17","doi-asserted-by":"crossref","unstructured":"Lee SM, Fan W, Wang A, Vaidya R, Redman MW, Gettinger SN, et al. Novel approaches for dynamic visualization of adverse event data in oncology clinical trials: a case study using immunotherapy trial S1400-I (SWOG). JCO Clin Cancer Inform. 2023;7.","DOI":"10.1200\/CCI.22.00165"},{"key":"6062_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000491038","volume":"51","author":"L Vannucci","year":"2019","unstructured":"Vannucci L, Brandi ML. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Front Horm Res. 2019;51:52\u201362.","journal-title":"Front Horm Res"},{"key":"6062_CR19","doi-asserted-by":"crossref","unstructured":"Russell P, Antony MA. Coexistence of a calcium-sensing receptor mutation and primary hyperparathyroidism. Cureus. 2023;15.","DOI":"10.7759\/cureus.46980"},{"key":"6062_CR20","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/ejendo\/lvae035","volume":"190","author":"C Saglia","year":"2024","unstructured":"Saglia C, Arruga F, Scolari C, Kalantari S, Albanese S, Bracciam\u00e0 V, et al. Functional evaluation of a novel nonsense variant of the calcium-sensing receptor gene leading to hypocalcemia. Eur J Endocrinol. 2024;190:296\u2013306.","journal-title":"Eur J Endocrinol"},{"key":"6062_CR21","first-page":"1902","volume":"29","author":"P Stratta","year":"2014","unstructured":"Stratta P, Merlotti G, Musetti C, Quaglia M, Pagani A, Izzo C, et al. Calcium-sensing-related gene mutations in hypercalcaemic hypocalciuric patients as differential diagnosis from primary hyperparathyroidism: detection of two novel inactivating mutations in an Italian population. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2014;29:1902\u20139.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc"},{"key":"6062_CR22","first-page":"167","volume":"10","author":"L Tian","year":"2024","unstructured":"Tian L, Andrews C, Yan Q, Yang JJ. Molecular regulation of calcium-sensing receptor (CaSR)-mediated signaling. Chron Dis Transl Med. 2024;10:167\u201394.","journal-title":"Chron Dis Transl Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06062-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06062-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06062-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T05:34:28Z","timestamp":1777095268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06062-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6062"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06062-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to local institutional regulations, formal ethical approval was not required for anonymized single case reports. Written informed consent for participation was obtained from both patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from both patients for publication of this case report and any accompanying images. Copies of the written consent are available for review by the Editor-in-Chief of this journal upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"221"}}